Keywords: Biotie Therapies, SYN120, Tozadenant, Selincro, Lundbeck, UCB

Biotie assets available for partnering; update on tozadenant

Article | 08 July 2012

Print This

Finland-based biotech firm Biotie Therapies’ (OMX: BTH1V) retention of SYN120 rights after Roche decided not to opt-in to ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in